ARCA biopharma Competitors, Revenue, Alternatives and Pricing

Claim your profile


Denver, CO USA
Total Funding:$90.4M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • ARCA biopharma's total funding is $90.4M.

Employee Data

  • ARCA biopharma has 26 Employees.(?)
  • ARCA biopharma currently has 1 job openings.

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado. The Company’s lead investigational product is Gencaro™ 1 (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications. ARCA’s New Drug Application for Gencaro for chronic heart failure, was accepted for filing by the U.S. Food and Drug Administration in September, 2008, and is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009.